Schizophrenia patients have higher scores on neurological soft-signs (NSS) and show greater deficits on a variety of neuropsychological tests than normal control subjects and mixed groups of psychiatric patients. Among chronic schizophrenia patients it is unclear which of these types of deficits most strongly differentiates patients who remain consistently symptomatic in spite of treatment with several conventional neuroleptics (nonresponders) as compared with relapsing chronic schizophrenia patients who improve substantially with treatment (relative responders). In this study, 25 nonresponders and 20 relative responders to conventional neuroleptics were compared on an NSS battery and a limited number of neuropsychological tests, which evaluated deficits influenced by functioning of frontal and nonfrontal brain areas. NSS scores showed the largest difference between relative responders and nonresponders, and statistical analyses suggested that NSS scores were the strongest differentiator between the two groups of chronic schizophrenia patients. Scores differentiating the two groups involved deficits influenced by both frontal and nonfrontal functioning. A predominance of negative symptoms in the current clinical picture was highly correlated with high NSS scores.
A proportion of patients with schizophrenia, estimated at 10 percent to 25 percent, show a persistently poor response to conventional pharmacological treatment. In spite of receiving adequate doses of multiple neuroleptics, these patients continue to manifest prominent psychotic symptoms and often remain hospitalized for years. A portion of this category of schizophrenia patients has been shown to respond to atypical neuroleptics (Kane et al. 1988; Meltzer 1992; .
Neurological soft-signs (NSS) are prevalent in patients with chronic schizophrenia, as well as among first-episode or untreated schizophrenia patients (Heinrichs and Buchanan 1988; Gupta et al. 1995) . Reports suggest that such signs are associated with a chronic course of illness, thought disorder, negative symptoms, and a deficit state. Some researchers believe neurological signs represent a trait characteristic of chronically ill schizophrenia patients (Heinrichs and Buchanan 1988; Buchanan et al. 1994) . Their relationship to treatment response is unclear. A few studies have reported lower NSS in acute or remitting schizophrenia or schizophreniform patients as compared with chronic schizophrenia patients (Torry 1980; Schroder et al. 1992 ). We are not aware of any published studies specifically comparing NSS in chronic relapsing schizophrenia patients who have shown a good response to conventional neuroleptics with chronically hospitalized schizophrenia patients who remain persistently symptomatic after treatment with these medications.
Schizophrenia patients show a broad range of neuropsychological impairments, including deficits in setshifting, verbal fluency, attention, and working memory (Goldstein 1986; Saykin et al. 1991) . Some of the tests that demonstrate performance problems with respect to these functions, such as the Wisconsin Card Sort (WCS) and Verbal Fluency tests, are thought to support the idea that brain pathology associated with such deficits is located in the frontal or prefrontal lobes. However, some recent studies and reviews have questioned this assumed specificity in functional localization (Perett 1974; Kolb and Whishaw 1983; Goldberg and Weinberger 1988; Andersen et al. 1991; Liddle and Morris 1991) . Other tests demonstrating problems in attention and copying are thought to reflect pathology in other brain "functional areas" or to indicate more general neurophysiological deficits (Lezak 1983) .
This article compares findings from neurological assessment and a limited number of neuropsychological tests (selected because they were putatively sensitive to frontal-and nonfrontal-mediated brain functioning) in two groups of hospitalized schizophrenia patients: (1) chronically hospitalized patients with a consistently poor or inadequate response to neuroleptics, and (2) hospitalized patients who had a substantial positive response to conventional neuroleptic medication. If there were significant differences between schizophrenia patients who were chronic nonresponders to traditional neuroleptics and schizophrenia patients who showed a substantial response to these medications on some of these measures but not on others, the findings might be informative in at least two ways. They might provide clues to guide future researchers in identifying functional brain areas that might differ in these two types of schizophrenia patients. The results might also point to measures that would be the most useful candidates for further investigation in identifying tests that could predict medication refractoriness in the course of schizophrenia.
Method
Patients. Subjects for the study were patients with a DSM-IH-R (American Psychiatric Association 1987) diagnosis of chronic schizophrenia or schizoaffective disorder who were hospitalized on several chronic and subacute treatment wards of a State psychiatric hospital (with an inpatient census of 800-900 patients at the time of the study) and were fluent in spoken English. Demographic and other characteristics of patients are presented in table 1. Diagnosis was made by means of a DSM-IH-R checklist, using data from the patient's chart, an interview of the patient to supplement the history, and the results of the psychopathology rating scales described below. All patients had been treated with conventional neuroleptic drugs (i.e., not clozapine, risperidone, olanzapine, or quetiapine). All patients gave written informed consent for participation in the study. Patients were classified as either chronic nonresponders (NR) or relative responders (RR) on the basis of past clinical response. RR patients were defined as patients whose psychiatric history clearly documented the presence of active positive schizophrenia symptoms (hallucinations, delusions, severe thought disorder) at some time during their current episode of illness and who had responded to treatment with neuroleptics over several weeks or months. This response was defined as the patient's showing, at the time of entry into this study, no or very minimal positive symptoms, and no severe negative symptoms, as evaluated by their treating psychiatrist and confirmed by interview-assessed scores on several psychiatric rating scales. This was an overall evaluation, and cutoff scores on a specific scale were not used for this classification. The patient's remitted state had been present for at least several weeks. Most of these RR patients were relapsing schizophrenia patients who were transferred to the State hospital after several weeks or months at an acute treatment hospital because they had not shown optimal initial response to neuroleptics or there had been problems in arranging disposition. A few of the RR patients had been hospitalized at the State facility for more than a year because of social or administrative problems in securing appropriate community placement.
NR patients had been hospitalized for more than a year at the State facility. They had been treated with adequate doses of several conventional neuroleptics and had continued to show prominent positive symptoms and persistent severe negative symptoms of schizophrenia. If a nonresponder was included mainly on the basis of severe negative symptoms, the criterion for inclusion was that these symptoms prevented the patient from substantial participation in any social rehabilitation program, as determined by review of chart records and discussion with members of the patient's treatment team.
Patients who had clinically significant and currently symptomatic neurological or medical illnesses, who had documented AIDS or HIV-positive status, or who had significant drug abuse in the past 2 months were excluded from the sample. However, we did not collect extensive data on all previous neurological abnormalities or physical traumas. RR patients whose current episode of psychosis was precipitated by abuse of psychotomimetic or stimulant drugs, and whose positive psychotic symptoms completely disappeared within a week or two after the initiation neuroleptic treatment, were also excluded from the sample regardless of whether they fulfilled DSM-III-R criteria for schizophrenia on the basis of prior episodes of their psychiatric history.
Procedures.
Patients were evaluated for current psychiatric symptoms with the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham 1962) , Scale for the Assessment of Negative Symptoms (SANS; Andreasen 1984a), and Scale for the Assessment of Positive Symptoms (SAPS; Andreasen 19846) . (Patients with no symptoms on a specific item receive a score of 1 on the BPRS and 0 on the SAPS and SANS scales.) All psychopathology ratings were performed by a single rater, usually within 1 week of the NSS exams. Because these ratings were all performed by the same rater, interrater reliability was not obtained. Patients were evaluated for NSS using a scale modified slightly from that proposed by Buchanan and Heinrichs (1989) , by addition of 3 and deletion of 2 items, based on reviews of other scales and the suggestions of a double-boarded neuropsychiatric consultant. The analysis presented in this paper uses both NSS total score (sum of scores on all items) and NSS component scores described in the original Buchanan and Heinrichs paper. The NSS motor sequencing score is the sum of first-ring, first-edge-palm, and Oseretsky procedures; the NSS motor coordination score is the sum of tandem walk, rapid alternating movements, and fingerthumb opposition; and the NSS sensory integration score is the sum of graphesthesia, stereognosis, two-point discrimination, and right/left confusion. Interrater reliability for total and component scores on the NSS scale, assessed by the intraclass correlation coefficient (ICC; Shrout and Fleiss 1979) from joint ratings by two examiners on a series of patients, were as follows: NSS total = 0.93; NSS Motor Sequencing subscore = 0.88; Motor Coordination subscore = 0.82; Sensory Integration subscore = 0.84. Subjects were also administered a series of neuropsychological tests assessing verbal fluency, shifting sets, attention, and other neuropsychological functions (Lezak 1983) . These tests included the following: modified WCS (Nelson 1976) , verbal fluency (VF; three tests using letters, groceries, and animals), digit-span (DS; Wechsler 1981) , and graphomotor test (adapted from Dementia Rating Scale [Mattis 1973] ). Thirty-seven subjects also received the Trail Making test (forms A and B; Lezak 1983 ). All subjects were tested when they had been on stable doses of conventional neuroleptics for several weeks or months and their symptoms had not significantly fluctuated for at least 2 weeks, as evaluated by their treating physician. One chronically hospitalized NR patient, who was psychotic, could not complete several test procedures because his thought processes and behavior were too disorganized to cooperate. He was later switched to clozapine. He remained severely psychotic and thought disordered on this medication, but he was able to cooperate with neuropsychological tests, and therefore, test results on this single subject are reported from tests performed when he was receiving clozapine. Neurological and neuropsychological tests were performed by testers who were aware of the nature of the study and the general clinical status of the patients but not patients' specific psychopathology scale scores or specific hypotheses subsequently analyzed. Subjects were administered the NSS scale and neuropsychological tests over 3 to 8 sessions during a 1-to 3-week period. NSS and neuropsychological tests were administered in different sessions. There was no specific order of neuropsychological test administration. Number of sessions and session length (range 15-50 minutes) were determined by subjects' ability to cooperate with and attend to the testing. Many patients in the NR group had to be tested in multiple brief sessions because of inability to cooperate with testing for an extended period of time. If a patient failed to complete a test because of poor cooperation in one session so that data sufficient to generate scores could not be obtained, the patient was retried on the test in a subsequent session. Occasional subjects did not complete all the administered tests because of persistent problems with cooperation or limited attention.
Statistical Analysis. Statistical analyses were performed with the SPSS and GB-Stat programs. To determine whether a test measure was significantly higher in the NR versus RR groups of patients, 2-sample t tests with pooled or separate variance (sv) were used. Statistical significance of the test results was expressed for the individual t tests. Significance levels protected for multiple t tests performed, using the Bonferroni procedure, were also calculated for an uncorrected alpha = 0.05. The influence of patients' sex and other background variables was examined with analyses of variance and covariance. Scores for Trails A and Trails B (seconds for completion) with distributions appearing to deviate substantially from a normal distribution were log transformed before being subjected to statistical analysis. Since the distribution of the difference between performance in Trails A and B was not so skewed, and log transformation did not improve normality, the raw scores were used for this difference measure. When distribution of test scores deviated markedly from a normal distribution and a subject's responses fell into a few categories, the X 2 test was used. For the subset of subjects for whom there was complete data on the neurological and neuropsychological tests, a multivariate analysis of variance was performed with univariate tests for each variable. To further examine which factors were most important in differentiating NR versus RR patients, a step-down discrimination function analysis was performed using minimalization of Wilk's lambda as the test criteria. Relationships between neurological or neuropsychological test variables and psychopathology scores were examined by correlation and regression analysis.
Results

Background Characteristics NR and RR Group.
Chronic NRs had substantially higher psychopathology scores on both positive (SAPS, BPRS Psychosis factor) and negative (SANS, BPRS Anergia factor) symptoms than RRs who had low symptom scores (table 1). Scores on positive symptoms for patients in the RR group represented very low symptom levels or absence of symptoms (e.g., mean SAPS Global = 1.2, score for no symptoms = 0). Although NR patients had substantially higher negative symptom scores than RR patients, both RR and NR groups had negative symptom scores, which indicated the presence of negative symptoms (e.g., mean score SANS Global NR = 13.6, RR = 6.0, no symptoms = 0). NR patients had longer hospitalizations for current episode and longer duration of illness than RR patients, less history of drug abuse, and slightly lower mean years of education. However, there were no significant differences between the groups in age, sex, race, diagnosis, age at onset of illness, or neuroleptic dosage (in chlorpromazine (CPZ) equivalents) at the time of testing. Approximately 74 percent of the RR patients were on concomitant antiparkinsonian medication compared with only 38 percent of the patients in the NR group. Ninety-five percent of the RR patients were on high-potency neuroleptics compared with 68 percent of the NR patients.
Differences in NSS and Neuropsychological Tests
Between NR and RR Groups. A multivariate analysis of variance showed a highly significant difference between NR and RR patients on the battery of all neurological and neuropsychological tests (Hotellings T 2 = 2.090, F = 4.18, df= 12,24, p = 0.001). Subsequent univariate F tests showed significant group differences for NSS variables, verbal fluency, and some of the variables from the WCS and Trail Making Tests (see below). There were no significant correlations of age or current dosage (in CPZ equivalents) with any of the variables where analysis showed differences between NR and RR patients, either in the total sample or the separate groups of NR or RR patients. As expected, because of the significant differences between the NR and RR patients in total years ill, years of current hospitalization, and education, these variables correlated significantly with some of the test scores. However, within the NR or RR groups, there were no significant correlations between the background variables (i.e., years ill, years of current hospitalization, or years of education) and the NSS or verbal fluency variables. Two-way analysis of variance for the individual variables, which differed significantly between NR and RR patients, showed that there were no significant interactions of gender with group differences on any of the test scores. Differences between the NR and RR groups on the NSS and verbal fluency variables (except for the subscore of NSS sensory integration tasks) also remained statistically significant when patients' age, years ill, years of current hospitalization, and highest education were covaried in the analyses of covariance.
NSS showed the greatest difference between chronic nonresponders and relative responders. All patients in both the NR and RR groups showed at least minimal scores on the NSS exam, but NR patients had substantially and significantly higher numbers of NSS signs and higher scores on both NSS total and NSS component scores, except for reflexes (table 2) . Motor coordination scores showed the greatest increase in NRs and motor sequencing tasks were more than twice as severe. Most of the neuropsychological tests used in this study showed considerably smaller differences between NR and RR patients. Both NR and RR patients performed poorly on the WCS test, most achieving no more than one category, but NR patients had significantly more total and perseverative errors. However, there was no difference between NR and RR patients in percent perseverative errors, the main comparison variable used in some previous studies with the WCS in schizophrenia. Verbal fluency scores were significantly decreased in NR patients. NR patients had decreased speed of performance on Trails A but not on the more complex Trails B. There were no significant differences between NR and RR patients on several other tests. When significance levels were corrected for multiple tests performed, by the Bonferroni method, only differences between the NR and RR patients in NSS scores and verbal fluency remained statistically significant. English language skills can potentially affect scores on some neuropsychological tests, especially tests of verbal fluency. Although chi-square analysis revealed no significant difference in race between NR and RR groups (table 1) , there were a larger number of patients with Hispanic surnames in the NR group {n = 10) than in the RR group (n = 2). All patients spoke English fluently, but we did not specifically assess written or verbal fluency in English of subjects with Hispanic versus non-Hispanic surnames. Therefore, we specifically analyzed the effects of ethnicity, defined in terms of Hispanic versus nonHispanic surnames, on the difference between NR and RR groups for all the variables that showed a significant difference between the NR and RR groups shown in table 2. Two-way analyses of variance revealed no significant interaction effects between ethnicity and group (NR vs. RR) for any of the variables that showed statistically significant group differences. Furthermore, the NR versus RR group differences on the variables verbal fluency, NSS Total score, NSS Motor Sequencing, NSS Motor Coordination, WCS total errors, and Trails A remained statistically significant in the two-way analysis of variance in which ethnicity was one of the two factors in the analysis.
Because there were marked differences in psychopathology scores among the patients in the NR and RR groups, we wanted to investigate whether the statistically significant differences in NSS scores and some of the neuropsychological tests were accounted for primarily by differences in subjects' positive or negative symptoms. Analyses of covariance were performed for the measures that showed statistically significant differences between NR and RR groups, using either SAPS or SANS scores as a covariate. Three of the four NSS scores continued to show the highest and most consistent differences between groups when controlling for these psychopathology scores. Analysis of covariance, using SAPS Global as a covariate, showed significant group (NR vs. RR) effects for the following variables: NSS total, NSS Motor Sequencing, NSS Motor Coordination, Verbal Fluency (all with p < 0.005). Analysis of covariance using SANS Global as the covariate showed a significant group effect for the following variables: (at p s 0.006) NSS total, NSS Motor Sequencing, NSS Motor Coordination, WCS Total errors; (at p = 0.025) WCS percent perseverative responses.
To further evaluate which variables most effectively differentiated the NR and RR patient groups, step-down procedures were used to generate discriminant function equations (table 3) . The size of the standardized beta coefficient of a variable's score in the final discriminant equation suggests the strength of the variable's contribution to differentiating between the groups. The magnitude of the correlation of a variable with the discriminant function can also indicate the importance of the variable in differentiating the groups. When NSS component scores and 
Relationship Between Psychopathology Scores and NSS or Neuropsychological Test Scores.
Neurological soft-signs were strongly correlated with negative symptoms both in the total sample and within the NR group (table 4) . Motor sequencing, motor coordination, and a combined frontal task component, but not the sensory integration subscore of the NSS scale, were correlated with negative symptoms. Among the SANS component subscores, the SANS avolitional subscale had the highest correlation with NSS scores. In the NR patients, the degree to which negative symptoms predominated over positive symptoms in the patients' current clinical presentation also correlated significantly with NSS scores. For example, the difference between negative versus positive symptom score, defined as SANS Global minus SAPS Global score, correlated significantly with NSS scores (Pearson r = 0.44 to 0.56). Regression analysis indicated that a linear relationship provided a best fit for the relationship between NSS scores and negative symptom scores. WCS perseverative errors, on the other hand, were not significantly correlated with negative symptoms, and there was a nonsignificant trend for higher SANS scores to be correlated with a lower percentage of perseverative errors in the NR group. Positive symptoms were correlated with both NSS and WCS scores in the total sample, but these correlations were not significant within the NR and RR groups considered separately. The seemingly anomalous significant correlation between SAPS scores with NSS in the total sample, shown in table 4, is largely due to the effects of NR versus RR group differences in these scores, and this is illustrated graphically in figure 1 . In fact, in the NR patients, there were nonsignificant trends for higher positive symptom scores to be related to lower NSS scores.
Relationship Between NSS and Neuropsychological
Test Scores. NSS total and component scores were negatively correlated with verbal fluency scores (r = -0.62 to -0.71; p < 0.001) and NSS total and Motor Sequencing scores were moderately positively correlated with WCS total errors (r = 0.44 to 0.48; p <. 0.001) and perseverative errors (r = 0.27 to 0.31; p < 0.04), and with Trails A time to completion (r = 0.32 to 0.34; p < 0.03). When the NR and RR patients were examined separately, the negative correlation between NSS total score and verbal fluency was maintained, but the positive correlations between NSS scores and WCS variables were present only in the RR patients. Except for the negative correlation with ver- bal fluency, NSS sensory integration task scores were not significantly correlated with neuropsychological test scores.
Discussion
Neurological Soft-Signs and Persistently Symptomatic Schizophrenia. Our data indicate that differences in the number and severity of NSS strongly differentiated between chronic schizophrenia patients who were persistently symptomatic after treatment with conventional neuroleptics and those whose positive symptoms resolved after several weeks or months of treatment with these medications. These findings suggest that high NSS scores may predict patients who will fall into the category of patients with schizophrenia who are chronic nonresponders to conventional antipsychotics. However, a longitudinal study of a group of patients with schizophrenia, evaluating changes in NSS over time correlated with pertinent indices of clinical course, would be necessary to assess whether NSS measured at an earlier stage of illness will be predictive of a consistently poor response to these medications. Higher scores on tests of NSS have been reported in first-episode schizophrenia patients compared with control subjects (Gupta et al. 1995) and have been suggested to be a trait characteristic in chronic schizophrenia (Buchanan et al. 1994 ). But it is unclear whether NSS increase in severity over the course of the illness among any particular subgroup of patients with schizophrenia. If NSS severity evolved simply with duration of illness, one might expect NSS scores to correlate with age, number of years ill, or number of years of current hospitalization. The fact that, in this study, there were no significant correlations of these variables with NSS scores in either the NR or RR groups is not consistent with this expectation. Interestingly, in a small subset of the NR patients evaluated for NSS on a second occasion, 1 to 3 years later, there was no significant trend for NSS scores to increase in severity. Although our data indicate that NSS appeared to be the strongest differentiator between chronic NR and RR groups, this does not necessarily imply that lower NSS scores will be correlated with the extent of response to antipsychotic medication in short-or intermediate-term treatment trials. Because we did not assess the quantitative response to a neuroleptic trial from "baseline" to "endpoint," in NR versus RR patients, we cannot conclude that the percent decrease in rating scale scores would be different in the two patient groups. It is possible that the differences in positive and negative symptom scores in the two groups represent differences in illness severity, rather than differences in percent change in these symptoms during a defined treatment trial with conventional neuroleptics. A few other studies have tried to investigate the relationship of NSS to changes in rating scale scores during treatment with a neuroleptic. Several studies have failed to report a correlation between NSS and short-or intermediate-term outcome during treatment with traditional neuroleptics (Kolakowska et al. 1985; Buchanan et al. 1994) or with the atypical neuroleptic clozapine (Buchanan et al. 1994) . One study reported no relationship between NSS and reduction in positive symptoms, and a complex relationship with change in negative symptoms (Convit et al. 1994) . Two studies have reported changes in NSS in acute or relapsing schizophrenia patients hospitalized in primary care facilities during a short-term course of treatment with neuroleptics (Schroder et al. 1992; Scheffer et al. .1994) . However, the relationship of baseline NSS score to clinical outcome was not reported in these studies. We recently reported that severity of NSS correlated negatively with degree of reduction in positive symptoms in chronically hospitalized NR schizophrenia patients who were given a trial of risperidone for several months (Smith and Kadewari 1996) .
Frontal and Non-Frontal Task Differences Between
Groups. Performance oh the NSS motor sequencing and complex (go/no go) tasks, as well as verbal fluency and perseverative errors on the WCS are thought to be importantly influenced by processes mediated by neuronal connections in the frontal or prefrontal brain areas. The findings that these scores were significantly higher in chronic NR patients are consistent with the possibility of particular deficits in portions of the frontal lobe of these patients. However, our results are also consistent with recent reports suggesting that performance on the WCS may also be mediated by regions of brain functioning other than frontal lobes (Andersen et al. 1991) , and also that the WCS may not be the most discriminating neuropsychological test of performance deficits in schizophrenia patients (Saykin et al. 1991 (Saykin et al. , 1994 . The independence of WCS errors is supported by the findings that they showed a different pattern of correlation with clinical symptoms and that they contributed independently as a significant factor in the discriminant function analysis. The lower standardized beta of the WCS perseverative error score in the discriminant function equations and the lower correlation of the WCS scores with the discriminant function are consistent with some other recent reports indicating that, although these scores show deficits in schizophrenia patients, they are not the strongest difference between schizophrenia patients and normal control subjects (Saykin et al. 1991 (Saykin et al. , 1994 .
Interestingly, the score on the NSS showing the greatest percentage worsening in NR patients compared with RR patients was found in the motor coordination index, and this score also had the highest correlation with negative symptoms. Many of these tasks may be influenced by cerebellar functioning and also subcortical influences on the frontal lobes through the basal ganglia. This suggests that, in addition to greater frontal lobe deficits, NR patients may have more frequent subtle abnormalities in other parts of the brain, and these deficits may be equally or more important than frontal lobe cortical deficits in assigning a patient to the chronic NR group. Neuroanatomical and neurophysiological studies have identified pathways from the cerebellar fastigial nucleus to the hippocampus amygdala complex, which can modulate mesolimbic and mesocortical activity (Martin and Albers 1996) . Other studies have provided evidence that the basal ganglia play a major role in motor speed and coordination (Alexander et al. 1986) . Some structural and functional neuroimaging studies report anatomic or metabolic deficits in the cerebellum in patients suffering from schizophrenia compared with control subjects, specifically vermal atrophy and lower metabolism in the cerebellum (Weinberger et al. 1979; Heath et al. 1982; Dewain et al. 1983; Alexander et al. 1986; Volkow et al. 1992) . One careful recent magnetic resonance imaging study did not find any difference in cerebellar or other posterior fossa structures between schizophrenia patients and control subjects (Aylward et al. 1994) , but this study used chronic schizophrenia outpatients who were functioning in the community, not severely ill chronically hospitalized patients with schizophrenia who did not respond to neuroleptics. Andreasen and associates have presented evidence for structural abnormalities in subcortical structures in the brains of schizophrenia patients (Swayze et al. 1992; Andreasen et al. 1994) . This group has also presented evidence (Flashman et al. 1996 ) that schizophrenia patients with NSS have specific deficits in neuropsychological tests emphasizing motor speed and coordination. They interpret their findings as an indication of compromise in frontal and subcortical circuitry in schizophrenia.
NSS and Neuropsychological Test Scores.
The correlations between the NSS and neuropsychological test scores we report, which emphasize tasks that may be related to frontal lobe function, are generally consistent with the findings of Braun and associates (Braun et al. 1995) who reported significant correlations between the Nathan Kline Institute Neurological Soft-Sign Scale and neuropsychological test scores on the WCS performance and Trail Making tests. Braun et al. interpreted their findings as reflecting deficits in orbitofrontal functions. However, our strongest correlation, between NSS and verbal fluency, which may also represent deficits in frontal lobe function, was not reported as a significant correlation in the Braun study (Braun et al. 1995) . Flashman also did not report verbal fluency scores as being significantly different in schizophrenia patients with present versus absent NSS (Flashman et al. 1996) . This group reported the main association of NSS with a series of neuropsychological tests (finger tapping, Trail Making B, Rey-Osterrieth complex figure copy), which they identified primarily as motor tasks, and not with neuropsychological tasks identified with frontal lobe deficits. However, the Flashman study compared schizophrenia patients with and without NSS. All the schizophrenia patients in our study had one or more NSS, and even the RR patients had an average of seven positive signs. Moreover, the patients in our study, especially the NR patients, were chronically hospitalized and considerably more symptomatic than patients in either the Braun (Braun et al. 1995) or Flashman (Flashman et al. 1996) studies. These factors may contribute to the differences in relationship between NSS and neuropsychological performance in our study and the studies reviewed above.
NSS and Negative Symptom Schizophrenia. The association of NSS with negative symptoms is consistent with results of some previous studies. These studies have reported higher NSS scores in deficit compared with nondeficit schizophrenia patients (Buchanan et al. 1990 ) and correlations of NSS scores with BPRS Anergia and negative symptom measures on the Positive and Negative Syndrome Scale (Merriam et al. 1990; Schroder et al. 1992; Swayze et al. 1992; Andreasen et al. 1994) . In our NR patients, the significant correlations of negative symptom scores with NSS and also the correlations with NSS of the predominance of negative symptoms over positive symptoms in the clinical picture are consistent with the suggestion that these subtle expressions of brain abnormalities in NR patients may be associated with a negative symptom type of schizophrenia. However, because we did not classify our schizophrenia patients by Crow's Type I/Type II (Crow 1980) or Carpenter and associates' deficit versus nondeficit distinctions (Carpenter et al. 1988) , but only on current symptomatic negative symptom dimensions of SANS and BPRS scales, we cannot conclude that these correlations conclusively identify a distinct subgroup of patients with persistent negative syndrome schizophrenia. The pattern of correlations suggests that deficits in both frontal and nonfrontal areas contributed to the association of NSS scores with negative symptoms. This is consistent with some other recent reports (Perlick et al. 1992) . However, the lack of significant correlations between the sensory integration subscale of NSS scores and negative symptoms in our study contrasts with the significantly higher NSS sensory integration score in the deficit as compared with nondeficit subtypes of schizophrenia that Buchanan and associates reported (Buchanan etal. 1990 ).
Limitations of the Study. Several issues could poten : tially influence the validity or interpretation of the findings. It is possible that some neuroleptic side effects could correlate with NSS scores and be a confounding variable. Because we did not assess these patients on extrapyramidal side effects (EPS) scales, we cannot definitely rule out this possibility. However, for the following reasons we believe the group differences are unlikely to be explained by differences in neuroleptic side effects in the NR versus RR groups. In some studies neuroleptic side effects correlate with neuroleptic dose, but we found no correlation of NSS scores and dose expressed in CPZ equivalents. There was also no difference in neuroleptic dose between the NR and RR patients. EPS of neuroleptic drugs are often correlated with the patient's treatment with antiparkinsonian medication for these side effects. Thus we would expect that if NR patients had more EPS they would be more likely to receive antiparkinsonian medication. However, our results showed that NR patients received significantly less antiparkinsonian medication. Although we cannot be certain that all NR patients were treated with adequate doses of antiparkinsonian medications, or that less use of antiparkinsonian medications truly represents lower EPS symptoms, none of our NR patients had obvious or severe EPS. High-potency neuroleptics have been associated with more EPS than low-potency neuroleptics. However, a significantly lower percentage of NR patients were being treated with high-potency neuroleptics than RR patients. These results suggest that EPS were not likely to be higher in our NR than our RR patients. Furthermore, in two other samples of chronically hospitalized schizophrenia patients studied at the same institution, in which we measured both NSS and drug side effects, we have found no significant correlations of NSS total or component scores and side-effect scores measured either with the Scale for the Assessment of Movement Disorders (Alpert and Pouget, in preparation) or the Simpson-Angus Scale (Simpson and Angus 1970) . All Pearson correlation coefficients (r) were below 0.27, and most were below 0.12.
There was such a marked difference in the level of psychopathology and associated behaviors between the NR and RR patients that it was practically impossible to effectively blind group membership during testing, and it is theoretically possible that the NSS and other evaluations could be influenced by these perceptions. We have no way of definitively assessing this potential bias, but we believe that some additional data suggest that this perception may not have had an important influence on the assessment of NSS scores in this study. If there was a substantial bias of patients' clinical presentation or study hypotheses influencing NSS scores in our chronically hospitalized patients, then one might expect NSS scores to be significantly correlated with the fluctuations in the patients' psychopathology scores over time and to vary substantially if the patients were reevaluated when they took part in other types of studies. Preliminary data from a small number of chronically hospitalized schizophrenia patients reevaluated with this NSS scale and psychopathology ratings over the course of up to 3 years suggest that this is not the case. Total NSS scores were highly correlated (r = 0.76 to 0.86, p < 0.001), and changes in NSS scores at two time points were not significantly related to changes in BPRS, SAPS, and SANS scale scores.
This study was designed to include a small number of neuropsychological tests that reflected frontal and nonfrontal types of brain functions. We did not intend to use a comprehensive battery of neuropsychological tests. For example, our study did not assess neuropsychological measures of verbal learning, semantic memory, and spatial working memory, which, in some recent studies, show substantial differences between schizophrenia patients and normal control subjects (Saykin et al. 1991; Park and Holzman 1992; Saykin et al. 1994; Park et al. 1995) . Consequently, our results are not informative as to whether NSS scores are a more potent differentiator of NR and RR groups than neuropsychological tests, although they appear to be somewhat stronger than most of the limited number of neuropsychological tests used in this investigation.
Summary.
Our results show that high scores on NSS differentiated hospitalized schizophrenia patients who have shown a consistently poor or inadequate response to several conventional neuroleptics from those who showed substantial clinical response to these medications. The generalizability of this finding requires appropriate replication in similar comparison groups. The higher NSS component scores appear to reflect deficits in neurological signs influenced by both frontal and nonfrontal brain areas. An interesting question is whether high NSS scores measured relatively early in the course of schizophrenia will be predictive of patients falling into the NR patient category. The answer will require longitudinal studies. High NSS scores were associated with a predominantly negative symptom clinical presentation in our NR patients, but further longitudinal study is needed to determine if they are identified with a deficit syndrome or negative syndrome subtype of schizophrenia.
